Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
AstraZeneca
Boehringer Ingelheim
McKesson
Moodys

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR MOVANTIK


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Movantik

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02705378 ↗ The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit Withdrawn AstraZeneca Phase 3 2017-05-01 Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial.
NCT02705378 ↗ The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit Withdrawn Massachusetts General Hospital Phase 3 2017-05-01 Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial.
NCT02737059 ↗ Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects Completed AstraZeneca Phase 1 2016-07-01 This research study was being done to study the effect of codeine and Naloxegol for 3 days compared to placebo on the movement of food through the colon of healthy individuals. Codeine is a commonly used pain-relieving drug that often causes constipation as an unwanted side effect. Naloxegol is a medication recently approved by the FDA for treatment of constipation induced by Codeine. The hypothesis for this study was that Naloxegol reduces the retardation of small bowel and colonic transit induced by codeine in healthy participants.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Movantik

Condition Name

Condition Name for Movantik
Intervention Trials
Constipation 6
Constipation Drug Induced 3
Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Movantik
Intervention Trials
Constipation 9
Opioid-Induced Constipation 5
Critical Illness 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Movantik

Trials by Country

Trials by Country for Movantik
Location Trials
United States 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Movantik
Location Trials
Massachusetts 4
Ohio 4
Pennsylvania 3
North Carolina 2
New York 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Movantik

Clinical Trial Phase

Clinical Trial Phase for Movantik
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Movantik
Clinical Trial Phase Trials
Terminated 5
Withdrawn 3
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Movantik

Sponsor Name

Sponsor Name for Movantik
Sponsor Trials
AstraZeneca 8
Massachusetts General Hospital 2
Temple University 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Movantik
Sponsor Trials
Other 17
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
AstraZeneca
Colorcon
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.